A roadmap for prostate cancer treatment

April 03, 2000

The incidence of prostate cancer is increasing, as is the number of diagnostic and therapeutic interventions to manage this disease. Dr. Steven Grover and colleagues have developed the Montreal Prostate Cancer Model to follow a hypothetical cohort of men to estimate the probability of prostate cancer and the annual progression of the disease according to patient age, tumour stage and grade, and initial treatment.

The model's 10-year disease-specific survival estimates following prostatectomy for tumour grades 1, 2 and 3 were 96%, 92% and 84% respectively. In comparison, data from the Surveillance, Epidemiology and End Results (SEER) Program, based on more than 59 000 cases of localized prostate cancer, show rates of 98%, 91% and 76%, respectively.

Given the comparable results, the authors conclude that the Montreal Prostate Cancer Model can be used to guide decision-making for the management of prostate cancer and to forecast clinical outcomes for men with prostate cancer or who are at risk for the disease.

In an accompanying article the authors use the model to estimate the economic burden of prostate cancer. In a 1997 cohort of 5.8 million Canadian men aged 40 to 80 years prostate cancer would eventually be diagnosed in an estimated 701 491 men (12.1%) over their lifetime, and the direct medical costs would total $9.76 billion.

In an related commentary, Jaime Caro, Scientific Director of the Caro Institute in Concord, Mass., suggests that society should collectively invest in such disease-simulation models, rendering them public tools, in order to facilitate scientific scrutiny and replication.
-end-
The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model -- Dr. Steven Grover and colleagues

The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model -- Dr. Steven Grover and colleagues

Disease-simulation models and health care decisions -- Dr. Jaime Caro




Canadian Medical Association Journal

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.